Medistim ASA (LTS:0OCD) Retained Earnings: kr0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCD Medistim ASA LTS:0OCD
100 GF Score
Price kr231.00
GF Value kr260.85
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Retained Earnings?

Medistim ASA LTS:0OCD -0.86% 100 Retained Earnings is kr0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0OCD with a GF Score™ of 100/100 and a GF Value™ of kr260.85 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Medistim ASA's retained earnings for the quarter that ended in Mar. 2026 was kr0.0 Mil.

Medistim ASA's quarterly retained earnings increased from Sep. 2025 (kr0.0 Mil) to Dec. 2025 (kr368.8 Mil) but then declined from Dec. 2025 (kr368.8 Mil) to Mar. 2026 (kr0.0 Mil).

Medistim ASA's annual retained earnings increased from Dec. 2023 (kr307.4 Mil) to Dec. 2024 (kr328.8 Mil) and increased from Dec. 2024 (kr328.8 Mil) to Dec. 2025 (kr368.8 Mil).


Medistim ASA  (LTS:0OCD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Medistim ASA Retained Earnings Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Retained Earnings Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.16 285.74 307.38 328.80 368.82

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 368.82 0.00
LTS:0OCD
100GF Score
Medistim ASA LTS:0OCD
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of kr0.0 Mil mean?
Medistim ASA (LTS:0OCD) has a Retained Earnings of kr0.0 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Medistim ASA and its competitors.
Is Medistim ASA's Retained Earnings too high?
Medistim ASA's current Retained Earnings is kr0.0 Mil. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Retained Earnings compare to ABT and SYK?
Medistim ASA's Retained Earnings of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Medistim ASA and its competitors. Medistim ASA's current Retained Earnings is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Modestly Undervalued. The stock's GF Value™ is kr260.85, compared to a current price of kr231.00 — trading 11.4% below its estimated fair value. The current Retained Earnings is kr0.0 Mil. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current Retained Earnings is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (LTS:0OCD) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of kr231.00 is trading 11.4% below its estimated GF Value™ of kr260.85. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for LTS:0OCD:

  • Retained Earnings: kr0.0 Mil
  • GF Value™: kr260.85 vs. price of kr231.00 (11.4% below fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score

Get the complete analysis for LTS:0OCD

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr231.00
Price
kr260.85
GF Value